Skip to main content
Investors
Media
open in a new window
Contact Us
open in a new window
|
Search
open in a new window
Company
Science & Medicine
Patients
Responsibility
Careers
IR Home
Why Invest
Events & Presentations
Corporate Governance
Governance Documents
Executive Management
Board of Directors
Committee Composition
Contact the Board
Financials
Quarterly Results
Annual Reports
SEC Filings
Investor FAQs
Press Releases
Investor Contacts
Investor Emails Alerts
RSS Feeds
IR Home
Why Invest
Events & Presentations
Corporate Governance
Governance Documents
Executive Management
Board of Directors
Committee Composition
Contact the Board
Financials
Quarterly Results
Annual Reports
SEC Filings
Investor FAQs
Press Releases
Investor Contacts
Investor Emails Alerts
RSS Feeds
Close
Close
Investors
Company
Product
Research & Development
Patients
Partnerships
Careers
Close
Press Releases
Normal
Press Release RSS Feed (opens in new window)
Press release year list
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
November 5, 2019
Ironwood Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference
October 31, 2019
Ironwood Pharmaceuticals Reports Third Quarter 2019 Results; Raises Full Year 2019 Guidance
October 28, 2019
Ironwood Pharmaceuticals to Highlight New Data at the American College of Gastroenterology 2019 Annual Scientific Meeting
October 17, 2019
Ironwood Pharmaceuticals to Host Third Quarter 2019 Investor Update Call
September 18, 2019
Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS® (linaclotide) Collaboration in China
August 28, 2019
Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences
August 13, 2019
Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment
August 13, 2019
Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)
August 8, 2019
Ironwood Pharmaceuticals Announces Pricing of Upsized $350 Million Convertible Senior Notes Offering
August 6, 2019
Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes
July 30, 2019
Ironwood Pharmaceuticals Reports Second Quarter 2019 Results
July 18, 2019
Ironwood Pharmaceuticals to Host Second Quarter 2019 Investor Update Call
June 18, 2019
Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
June 13, 2019
Ironwood Pharmaceuticals to Establish New Headquarters in Downtown Boston
June 3, 2019
Ironwood Pharmaceuticals and Allergan Initiate Patient Dosing in Phase II Clinical Trial of MD-7246 in Patients with Abdominal Pain Associated with IBS-D
May 9, 2019
Ironwood Pharmaceuticals to Highlight IW-3718 and Linaclotide Data at Digestive Disease Week® 2019
May 7, 2019
Ironwood Pharmaceuticals to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference
May 2, 2019
Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA from Continuing Operations Guidance
April 18, 2019
Ironwood Pharmaceuticals to Host First Quarter 2019 Investor Update Call
April 16, 2019
Ironwood Pharmaceuticals Announces Adjustment of Conversion Rate for its 2.25% Convertible Senior Notes due 2020
April 1, 2019
Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company
March 14, 2019
Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement
March 7, 2019
Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference
March 4, 2019
Ironwood Pharmaceuticals to Present at Cowen Health Care Conference
February 26, 2019
Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering
February 21, 2019
Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
February 13, 2019
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update
January 28, 2019
Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Investor Update Call
January 28, 2019
Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation
January 15, 2019
Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in China for the Treatment of Adults with IBS-C
Download
PDF format download (opens in new window)
January 6, 2019
Ironwood Pharmaceuticals Appoints Michael Shetzline, M.D., Ph.D. as Chief Medical Officer
Download
PDF format download (opens in new window)
January 4, 2019
Ironwood Pharmaceuticals Announces Chief Executive Officers to Lead Ironwood and Cyclerion, Effective Upon Upcoming Separation
Download
PDF format download (opens in new window)
January 2, 2019
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
Download
PDF format download (opens in new window)
January 2, 2019
Ironwood and Allergan Announce Settlement with Mylan Resolving LINZESS® (linaclotide) Patent Litigation
Download
PDF format download (opens in new window)